BioRestorative Therapies Inc (BRTX)

[Babubd]

Gonna be a multi-Billion Dollars Company. Folks, let the PACER be updated and then BOOOOOOOM!! $BRTXQ

ACTUS FUND AND BRTXQ
Seeing what was happening, Actus Fund stepped in and partnered with the company to fund the company through bankruptcy and complete the FDA trials. In the U.S. and Europe, over 100 million people suffer from chronic back pain. Spinal fusion surgery costs $110,000. Discectomy costs anywhere from $20,000 to $50,000 and disk replacement surgery is $80,000 to $150,000. Compare this to what BRTXQ costs!

The company’s two core programs relate to the treatment of disc/spine disease and metabolic disorders.

DISC/SPINE PROGRAM (BRTXDISC™)
Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating, and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. BRTXQ received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

METABOLIC PROGRAM (THERMOSTEM®)
BRTXQ is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

HOW DID BIORESTORATIVE THERAPIES END UP IN BANKRUPTCY?
BRTXQ failed to raise between $10 million and $12 million for a clinical trial of its stem-cell therapy for bulging spinal discs, executives said in the filings. The trial was authorized by the U.S. Food and Drug Administration three years ago.

Board member and intellectual property attorney John M. Desmarais loaned the company $1.3 million, including interest, in 2016-17. Desmarais bid $500,000 through another business he owns, Phoenix Cell Group Holdings LLC. Phoenix was also providing $1.4 million to keep BioRestorative operating, the filings stated.

WHAT WAS DESMARAIS GAME PLAN?
His plan was to get the intellectual property owned by BRTXQ on the cheap. Basically, he thought he could steal the company. After all, he is a patent attorney and was a board member. He knows the true value of the patents!

https://insiderfinancial.com/biorestorative-therapies-brtxq-must-own/180510/